HCA Healthcare (2BH) AI Stock Analysis

Company Guidance

For 2027, HCA expects demand to remain strong, with volume growth forecasted to be 2% to 3%; it expects approximately $550 million to $650 million less in Medicaid supplemental payment net benefits, anticipates favorable cost performance primarily due to its ongoing enterprise wide resiliency program and operating leverage from expected volume growth, and anticipates earnings will be generally consistent with 2026. Beyond 2027, performance is expected to be more in line with long term growth targets, assuming the company moves past the most significant effects on payer mix from the exchanges, assumes no material policy changes beyond HR1, and strategic initiatives generate significant value. For 2026, guidance ranges were reaffirmed, with results currently expected to be in the upper half of those ranges; incremental net benefits from Medicaid supplemental payment programs are expected to be between $600 million and $800 million, while the full year unfavorable impact on adjusted EBITDA from payer mix shifts is expected to be at or slightly above the upper end of the range of previously updated guidance.